Literature DB >> 19777211

The human cardiac K2P3.1 (TASK-1) potassium leak channel is a molecular target for the class III antiarrhythmic drug amiodarone.

Jakob Gierten1, Eckhard Ficker, Ramona Bloehs, Patrick A Schweizer, Edgar Zitron, Eberhard Scholz, Christoph Karle, Hugo A Katus, Dierk Thomas.   

Abstract

Two-pore-domain (K(2P)) potassium channels mediate background potassium currents, stabilizing resting membrane potential and expediting action potential repolarization. In the heart, K(2P)3.1 (TASK-1) channels are implicated in the cardiac plateau current, I ( KP ). Class III antiarrhythmic drugs target cardiac K(+) currents, resulting in action potential prolongation and suppression of atrial and ventricular arrhythmias. The objective of this study was to investigate acute effects of the class III antiarrhythmic drug amiodarone on human K(2P)3.1 channels. Potassium currents were recorded from Xenopus oocytes using the two-microelectrode voltage clamp technique. Amiodarone produced concentration-dependent inhibition of hK(2P)3.1 currents (IC(50) = 0.40 microM) with maximum current reduction of 58.1%. Open rectification properties that are characteristic to hK(2P)3.1 currents were not altered by amiodarone. Channels were blocked in open and closed states in reverse frequency-dependent manner. hK(2P)3.1 channel inhibition was voltage-independent at voltages between -40 and +60 mV. Modulation of protein kinase C activity by amiodarone does not contribute to hK(2P)3.1 current reduction, as pre-treatment with the protein kinase C inhibitor, staurosporine, did not affect amiodarone block. Amiodarone is an inhibitor of cardiac hK(2P)3.1 background channels. Amiodarone blockade of hK(2P)3.1 may cause prolongation of cardiac repolarization and action potential duration in patients with high individual plasma concentrations, possibly contributing to the antiarrhythmic efficacy of the class III drug.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19777211     DOI: 10.1007/s00210-009-0454-4

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  31 in total

Review 1.  Amiodarone for atrial fibrillation.

Authors:  Peter Zimetbaum
Journal:  N Engl J Med       Date:  2007-03-01       Impact factor: 91.245

2.  The acid-sensitive potassium channel TASK-1 in rat cardiac muscle.

Authors:  Caroline Putzke; Konstantin Wemhöner; Frank B Sachse; Susanne Rinné; Günter Schlichthörl; Xian Tao Li; Lucas Jaé; Ines Eckhardt; Erhard Wischmeyer; Hinnerk Wulf; Regina Preisig-Müller; Jürgen Daut; Niels Decher
Journal:  Cardiovasc Res       Date:  2007-02-28       Impact factor: 10.787

Review 3.  Cardiac channelopathies.

Authors:  Eduardo Marbán
Journal:  Nature       Date:  2002-01-10       Impact factor: 49.962

4.  TASK, a human background K+ channel to sense external pH variations near physiological pH.

Authors:  F Duprat; F Lesage; M Fink; R Reyes; C Heurteaux; M Lazdunski
Journal:  EMBO J       Date:  1997-09-01       Impact factor: 11.598

5.  Control of cardiac rhythm by ORK1, a Drosophila two-pore domain potassium channel.

Authors:  Nathalie Lalevée; Bruno Monier; Sébastien Sénatore; Laurent Perrin; Michel Sémériva
Journal:  Curr Biol       Date:  2006-08-08       Impact factor: 10.834

6.  Proton block and voltage gating are potassium-dependent in the cardiac leak channel Kcnk3.

Authors:  C M Lopes; P G Gallagher; M E Buck; M H Butler; S A Goldstein
Journal:  J Biol Chem       Date:  2000-06-02       Impact factor: 5.157

Review 7.  The novel antiarrhythmic drug dronedarone: comparison with amiodarone.

Authors:  Sven Kathofer; Dierk Thomas; Christoph A Karle
Journal:  Cardiovasc Drug Rev       Date:  2005

8.  An open rectifier potassium channel with two pore domains in tandem cloned from rat cerebellum.

Authors:  D Leonoudakis; A T Gray; B D Winegar; C H Kindler; M Harada; D M Taylor; R A Chavez; J R Forsayeth; C S Yost
Journal:  J Neurosci       Date:  1998-02-01       Impact factor: 6.167

9.  Activation of protein kinase C epsilon inhibits the two-pore domain K+ channel, TASK-1, inducing repolarization abnormalities in cardiac ventricular myocytes.

Authors:  Alessandra Besana; Andrea Barbuti; Miyuki A Tateyama; Aviva J Symes; Richard B Robinson; Steven J Feinmark
Journal:  J Biol Chem       Date:  2004-06-07       Impact factor: 5.157

10.  Inhibition of calmodulin and protein kinase C by amiodarone and other class III antiarrhythmic agents.

Authors:  P J Silver; M J Connell; K M Dillon; W R Cumiskey; W A Volberg; A M Ezrin
Journal:  Cardiovasc Drugs Ther       Date:  1989-10       Impact factor: 3.727

View more
  15 in total

1.  PKC-dependent activation of human K(2P) 18.1 K(+) channels.

Authors:  Ann-Kathrin Rahm; Jakob Gierten; Jana Kisselbach; Ingo Staudacher; Kathrin Staudacher; Patrick A Schweizer; Rüdiger Becker; Hugo A Katus; Dierk Thomas
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

2.  Breathing Stimulant Compounds Inhibit TASK-3 Potassium Channel Function Likely by Binding at a Common Site in the Channel Pore.

Authors:  Rikki H Chokshi; Aaron T Larsen; Brijesh Bhayana; Joseph F Cotten
Journal:  Mol Pharmacol       Date:  2015-08-12       Impact factor: 4.436

3.  Atrial-selective sodium channel block by dronedarone: sufficient to terminate atrial fibrillation?

Authors:  Joachim R Ehrlich; Dobromir Dobrev
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-05-04       Impact factor: 3.000

Review 4.  The role of acid-sensitive two-pore domain potassium channels in cardiac electrophysiology: focus on arrhythmias.

Authors:  Niels Decher; Aytug K Kiper; Caroline Rolfes; Eric Schulze-Bahr; Susanne Rinné
Journal:  Pflugers Arch       Date:  2014-11-19       Impact factor: 3.657

Review 5.  Mechanisms and Drug Development in Atrial Fibrillation.

Authors:  David Calvo; David Filgueiras-Rama; José Jalife
Journal:  Pharmacol Rev       Date:  2018-07       Impact factor: 25.468

6.  Effects of exercise training on excitation-contraction coupling and related mRNA expression in hearts of Goto-Kakizaki type 2 diabetic rats.

Authors:  K A Salem; M A Qureshi; V Sydorenko; K Parekh; P Jayaprakash; T Iqbal; J Singh; M Oz; T E Adrian; F C Howarth
Journal:  Mol Cell Biochem       Date:  2013-04-26       Impact factor: 3.396

7.  Carvedilol targets human K2P 3.1 (TASK1) K+ leak channels.

Authors:  K Staudacher; I Staudacher; E Ficker; C Seyler; J Gierten; J Kisselbach; A-K Rahm; K Trappe; P A Schweizer; R Becker; H A Katus; D Thomas
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

8.  Functional characterization of zebrafish K2P18.1 (TRESK) two-pore-domain K+ channels.

Authors:  Ann-Kathrin Rahm; Felix Wiedmann; Jakob Gierten; Constanze Schmidt; Patrick A Schweizer; Rüdiger Becker; Hugo A Katus; Dierk Thomas
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-12-06       Impact factor: 3.000

9.  Novel pharmacological approaches for antiarrhythmic therapy.

Authors:  Ursula Ravens
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-01-15       Impact factor: 3.000

10.  Modulation of K2P 2.1 and K2P 10.1 K(+) channel sensitivity to carvedilol by alternative mRNA translation initiation.

Authors:  J Kisselbach; C Seyler; P A Schweizer; R Gerstberger; R Becker; H A Katus; D Thomas
Journal:  Br J Pharmacol       Date:  2014-08-28       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.